Small Molecules

10 Jun 2020 Bacainn Therapeutics Announces IND Clearance for BT051 and Initiation of Phase 1 Clinical Trial, Bacainn’s First Clinical Candidate for the Treatment of Ulcerative Colitis
10 Jun 2020 Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) for Children and Adolescents With Cystic Fibrosis Between the Ages of 6 Months and 18 Years With the R117H Mutation in the CFTR Gene
09 Jun 2020 Versant Ventures Launches Lycia Therapeutics with $50 Million
09 Jun 2020 Soleno Therapeutics Announces Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome
09 Jun 2020 A2A Pharmaceuticals Collaborates With LAXAI Life Sciences to Co-develop SARS-CoV-2 Main Proteases Inhibitors for the Treatment of COVID-19
08 Jun 2020 Cognition Therapeutics Receives $75.8 Million NIA Grant for 540-Patient Phase 2 Study of CT1812 in Collaboration with the Alzheimer's Clinical Trials Consortium
08 Jun 2020 IDEAYA Announces Nomination of Development Candidate, IDE397, for MAT2A Synthetic Lethality Program Targeting MTAP-Deletion Patient Population
08 Jun 2020 Neurocrine Biosciences Reports Positive Phase II Data for Crinecerfont in Adults with Congenital Adrenal Hyperplasia at ENDO Online 2020
08 Jun 2020 Insmed Receives FDA Breakthrough Therapy Designation for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)
08 Jun 2020 Roxadustat Demonstrates Non-Inferiority to Darbepoetin in Phase 3 DOLOMITES Study of Anemia in Non-Dialysis-Dependent Adult Patients with Chronic Kidney Disease
07 Jun 2020 AbbVie Presents Data Showing RINVOQ™ (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Head-to-Head Study Versus ORENCIA (abatacept) in Rheumatoid Arthritis Patients
05 Jun 2020 FDA Approves Antibiotic to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
05 Jun 2020 Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile at 52 Weeks in FINCH 1 and 3 Studies in Rheumatoid Arthritis
05 Jun 2020 Bayer submits vericiguat for marketing authorization in the EU and Japan for the treatment of chronic heart failure
03 Jun 2020 Complexa Completes Patient Enrollment in Phase 2 FIRSTx Trial Evaluating CXA-10 in Focal Segmental Glomerulosclerosis, a Rare and Severe Form of Kidney Disease
03 Jun 2020 Pierre Fabre Receives European Approval for BRAFTOVI® (encorafenib) in Combination With Cetuximab for the Treatment of Adult Patients With BRAFV600E-Mutant Metastatic Colorectal Cancer
03 Jun 2020 Menlo Therapeutics Announces Positive Results from Phase 2 Trial of FCD105 for the Treatment of Moderate-to-Severe Acne Vulgaris
03 Jun 2020 Mirum’s Maralixibat Demonstrates Transplant-Free Survival for Pediatric Patients with Progressive Familial Intrahepatic Cholestasis
03 Jun 2020 Bristol Myers Squibb Announces Positive Topline Results from Pivotal Phase 3 True North Trial Evaluating Zeposia (ozanimod) in Patients with Moderate to Severe Ulcerative Colitis
03 Jun 2020 Asana BioSciences Announces Positive Topline Results from Phase 2b Study of Oral JAK/SYK Inhibitor Gusacitinib (ASN002) in Patients with Chronic Hand Eczema: Rapid and Significant Improvement Demonstrated
03 Jun 2020 Treadwell Therapeutics Announces US FDA Clearance of IND Application for Phase 1/2 Study of HPK1 Inhibitor, CFI-402411
02 Jun 2020 Nicox Initiates First Phase 3 Trial of NCX 470 in Glaucoma
01 Jun 2020 Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
01 Jun 2020 Antibe Therapeutics Announces Positive Top-Line Data From Phase 2B Dose-Ranging, Efficacy Study For ATB-346
01 Jun 2020 AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top